Charlot Biosciences (CBio) was founded with the mission to innovate diagnostic test kits using advanced microfluidics and machine vision technologies. The company focuses on developing analytical equipment to ensure the efficacy of cell and viral vector gene therapies. Their flagship platform, cellPhoresis®, leverages novel separation science techniques, machine vision, and edge computing to identify hidden differences in cell populations, enhancing the accuracy and reliability of pathogen detection.
Notable figures affiliated with CBio include experts in biotechnology and diagnostics, although specific names are not provided. The company has secured investments from key players in the biotech industry, contributing to its rapid development and deployment of cutting-edge diagnostic solutions. CBio's achievements include successful pilot studies identifying neural stem and progenitor cell subpopulations, demonstrating the platform's potential to revolutionize diagnostic testing and improve patient care outcomes.
